



Creation of New Share Option Plan

Liege, Belgium, 19 December 2023 – 17:45 CEST – Mithra Pharmaceuticals SA (the "Company" or "Mithra") (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that its board of directors has issued, within the framework of the authorised capital, a new share option plan for eligible personnel, covering 7,615,500 share options (the "2023 Share Option Plan").

The share options under the 2023 Share Option Plan have a term of ten years (unless contractually reduced in the grant to a selected participant) and can be exercised in accordance with the provisions of the 2023 Share Option Plan (the conditions of which can be found on the Company's website). Each share option gives the right to subscribe for one new share of the Company. The share options will not be listed on any stock market.

The purpose of the 2023 Share Option Plan is to create a share option plan for eligible members of the personnel of the Company (defined in accordance with article 1:27 of the Belgian Companies and Associations Code), taking into account the recent expiration of the 2018 share option plan.

The reports prepared by the board of directors and the Company's statutory auditor (in accordance with article 7:198 *juncto* articles 7:180 and 7:191 of the Belgian Companies and Associations Code) with respect to the creation of the 2023 Share Option Plan are available on the Company's website.

For more information, please contact:

Mithra Pharmaceuticals SA

Alex Sokolowski, PhD
Head of IR & Communications
investorrelations@mithra.com
+32 (0)4 349 28 22

Frédérique Depraetere
Communications Director
info@mithra.com
+32 (0)4 349 28 22

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle[®], Mithra is now focusing on its second product Donesta[®], the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE[®] and DONESTA[®] are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media:

[Linkedin](#) • [X](#) • [Facebook](#)